Vincent Vultaggio Sells 6,894 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Vincent Vultaggio sold 6,894 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $2.42, for a total transaction of $16,683.48. Following the transaction, the insider owned 146,506 shares in the company, valued at approximately $354,544.52. The trade was a 4.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vincent Vultaggio also recently made the following trade(s):

• On Monday, February 9th, Vincent Vultaggio sold 3,379 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.39, for a total transaction of $8,075.81.
• On Friday, February 6th, Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.43, for a total transaction of $72,780.93.
• On Tuesday, February 3rd, Vincent Vultaggio sold 556 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.52, for a total transaction of $1,401.12.
• On Monday, February 2nd, Vincent Vultaggio sold 2,540 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.55, for a total value of $6,477.00.

Zentalis Pharmaceuticals Trading Up 1.3%

Shares of Zentalis Pharmaceuticals stock opened at $2.43 on Thursday. The business’s fifty day moving average price is $2.14 and its 200 day moving average price is $1.74. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $3.95. The stock has a market capitalization of $175.57 million, a P/E ratio of -1.17 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZNTL. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Leerink Partners reissued a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Morgan Stanley decreased their price target on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $27,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Qube Research & Technologies Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $37,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth $38,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.